|
 |
ZiagenThis page contains recent news articles, when available, and an overview of Ziagen but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Ziagen (when available) Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Abacavir is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. For the treatment of HIV-1 infection, in combination with other antiretroviral agents Mechanism Of Action: Abacavir is a carbocyclic synthetic nucleoside analogue. Intracellularly, Abacavir is converted by cellular enzymes to the active metabolite carbovir triphosphate, an analogue of deoxyguanosine-5'-triphosphate (dGTP). Carbovir triphosphate inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. News Articles on Abacavir Epzicom Associated With More Side Effects In HIV/AIDS Patients Than Truvada - Nov 9, 2009 Alternatively, Epzicom is a combination therapy that contains Ziagen (abacavir) and Epivir (lamivudine). Viread and Ziagen were originally introduced to ... The AIDS Beacon (blog) GlaxoSmithKline-Pfizer launch HIV joint venture - Nov 4, 2009 ViiV's existing drugs are nucleoside reverse transcriptase inhibitors (NRTIs): Combivir, Epivir/3TC, Epzicom/Kivexa, Retrovir/AZT, Trizivir and Ziagen. ... Pharmafocus Drug safety and your DNA - Oct 30, 2009 The HIV/AIDS drug abacavir (trade name Ziagen) is used to treat HIV by helping inhibit an enzyme that helps the virus reproduce. ... Common Ground.ca Glaxo und Pfizer gründen Joint Venture - Nov 3, 2009 GSK steuert die Kombinationsmittel Combivir, Kivexa, und Trizivir sowie die Monopräparate Epivir, Telzir, Retrovir ud Ziagen bei. ... apotheke-adhoc U project looks to future - 30 Aug 2009 As of June 30, licensing revenue (excluding AIDS drug Ziagen) totaled $8.67 million, an 11.1 percent jump from the same period last year. Minneapolis Star Tribune Tenofovir Not Necessarily Hard on the Kidneys - Aug 28, 2009 Tenofovir (found in Viread, Truvada and Atripla) as part of a first HIV regimen isn't necessarily harder on the kidneys than drugs such as Ziagen (abacavir) AIDSmeds.com HIV/AIDS Treatment News Abacavir as potent as tenofovir for patients starting HIV ... - Aug 6, 2009 Regardless of baseline viral load, an HIV treatment combination that includes abacavir (Ziagen, also in the combination pill Kivexa) is just as effective at Aidsmap Drug therapies firm gains traction: Medication Management, using U ... - Aug 24, 2009 Excluding the U's blockbuster anti-AIDS drug Ziagen, the school generated $8.67 million, an 11.1 percent gain from 2008. Since 2006, the U has spun off four TMCnet New HIV Guidelines Push 'Adherence to Care' - Aug 14, 2009 Testing for the HLA-B*5701 haplotype -– which increases the risk of an abacavir (Ziagen) hypersensitivity reaction -- should be done before starting therapy MedPage Today High Viral Load Patients Equally Fine on Epzicom or Truvada - Aug 7, 2009 People who start antiretroviral treatment for the first time with a viral load over 100000 do equally well on a regimen containing abacavir (found in Ziagen AIDSmeds.com HIV/AIDS Treatment News Treatments news from the IAS Conference - Aug 19, 2009 Two studies presented at IAS found no association between abacavir (Ziagen and also in the Kivexa combination pill) and increased risk of heart attackA NAPWA Glaxo promises $97M for new AIDS R&D initiative - 14 Jul 2009 GlaxoSmithKline also provided a free license to Ziagen for the South African generic company Aspen. Glaxo has been taking a lead role in demonstrating its FierceBiotech Glaxo investing $97 mln in AIDS drugs for Africa - 14 Jul 2009 It has also agreed a new free voluntary licensing agreement for AIDS drug abacavir, or Ziagen, with South African generic drugmaker Aspen Pharmacare (APNJ. Reuters Glaxo invertirá 97 mlns dlrs en fármacos contra sida para Africa - 14 Jul 2009 Glaxo también acordó una nueva licencia libre voluntaria para el fármaco abacavir, o Ziagen, con el laboratorio de genéricos sudafricano Aspen Pharmacare, Reuters América Latina Salute,Glaxo investirà 97 mln dollari per cure Aids in Africa - 14 Jul 2009 Glaxo ha anche stabilito un nuovo accordo gratuito di licenza per il medicinale anti-Aids Ziagen con il produttore di farmaci sudafricano Aspen Pharmacare, Reuters Italia Monogram Acquisition Bolsters LabCorp's PGx Test Portfolio ... - Jun 24, 2009 ...to LabCorp's assay for screening HIV patients for the HLA-B*5701 allele before initiating treatment with the drug abacavir (GlaxoSmithKline's Ziagen). GenomeWeb Daily News New HIV Drug Company Formed By Glaxo And Pfizer - Apr 17, 2009 ...comprises: Agenerase, Combivir, Epivir/3TC, Epzicom/Kivexa, Lexiva/Telzir, Rescriptor, Retrovir/AZT, Selzentry/Celsentri, Trizivir, Viracept and Ziagen. Medical News Today Five for the future: Minnesota's emerging industries - Mar 29, 2009 Its patents on Ziagen, an anti-AIDS drug that generates nearly 95 percent of its royalty income, will soon expire. Taylor's work could be the school's next Minneapolis Star Tribune WHO angry at seizure by Dutch of HIV drug shipment - Mar 12, 2009 However, GSK has let it been known that it did not believe its patent on abacavir, which it markets as Ziagen, had been infringed, and that it had no plans Pharma Times American Association For The Study Of Liver Diseases Conférence ... - Mar 6, 2009 ...mais cette étude vient rajouter à la suspicion d'interactions métaboliques entre RBV et ARV, comme cela a été décrit avec l'abacavir (Ziagen®, Kivexa®, ARCAT Hépatites actualités 65: Le congrès américain d'hépatologie 2007 ... - Mar 6, 2009 ...un risque accru d'échec du traitement anti-VHC chez les patients coïnfectés par le VIH et le VHC et prenant de l'abacavir (Ziagen®, Kivexa®, Trizivir®). ARCAT Doubt cast on cost-effectiveness of HLA-B*5701 screening for Asian ... - Jan 9, 2009 No HIV-positive Korean patients tested positive for the gene associated with hypersensitivity to abacavir (Ziagen), investigators report in the February 1 Aidsmap, Gilead Fourth-Quarter Profit Gains on AIDS Medicines - Jan 27, 2009 Gilead sales also are benefiting from studies last year that showed rival drugs Epzicom and Ziagen by GlaxoSmithKline Plc may be linked to treatment failure Bloomberg US Latinos have more unfavourable metabolic and body fat changes ... - Jan 16, 2009 ...nevirapine (Viramune), abacavir (Ziagen), ddI (didanosine, Videx), 3TC (lamivudine, Epivir), d4T (stavudine, Zerit) and AZT (zidovudine, Retrovir). Aidsmap, Morgan Joseph Initiates Coverage on Gilead Sciences (GILD) with a ... - Dec 9, 2008 Our optimism compared to Street estimates is due to three reasons: (1) we believe share gains of Atripla and Truvada against GSK's Ziagen are underestimated StreetInsider.com (subscription), Rare abacavir liver side-effects reported - Dec 2, 2008 Two cases of liver toxicity caused by the anti-HIV drug abacavir (Ziagen, also in the combination pill Kivexa) have been reported in the November 30 th Aidsmap, Cancer Med Labels May Reflect Genetic Issues - Dec 12, 2008 In July, Bloomberg points out, the FDA recommended testing patients for a gene, called HLA-B-5701 that causes a reaction in patients taking Glaxo’s Ziagen Pharmalot, Stock Report - Oct 14, 2008 His work has contributed to the discovery or development of multiple oncology and antiviral medicines and drug candidates, including Zeffix, Emtriva, Ziagen BuysellSignals, Médico Cirujano Abortista opera con sida. - Oct 7, 2008 Su tratamiento habitual incluye un comprimido diario de Epivir 300, dos de Zerit, dos de Ziagen, uno de Lopid 600, otro de Dianben, otro de Zyloric… asà El Periodico de Negocios del Ecuador, Gabon : Le commerce informel des médicaments brise l’élan des ... - Sep 10, 2008 La société a pu déterminer que des étiquettes contrefaites de comprimés de Combivir ont été placées sur deux flacons de Ziagen, les étiquettes sur deux InfosPlus Gabon, IAC: Abacavir (Ziagen) Linked Again with Higher Cardio Risk - Aug 8, 2008 8 -- A second major analysis has suggested that the nucleoside reverse transcriptase inhibitor abacavir (Ziagen) is associated with an increased risk of MedPage Today, Pooled-Analysis of 54 Clinical Studies Shows No Increased Risk of ... - Aug 6, 2008 ZIAGEN, in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in adults. ZIAGEN is one of 3 medicines MarketWatch UPDATE 1-US urges genetic test before using Glaxo AIDS drug - Jul 24, 2008 N: Quote, Profile, Research, Stock Buzz) drug, Ziagen, to see if they face a higher risk of a potentially fatal reaction, US regulators said on Thursday. Reuters Serious Reactions in Some to Ziagen, Abacavir, FDA Warns - Jul 25, 2008 Abacavir—sold under brand name Ziagen—therapy can result in HSRs in those patients who test positive for a particular human leukocyte antigen (HLA) allele Newsinferno.com, FDA Announces Important Safety-Related Label Update for Ziagen ... - Jul 23, 2008 ROCKVILLE, Md., July 23, 2008--On July 18, 2008, FDA approved changes to the package insert for Ziagen (abacavir sulfate) highlighting information about the PharmaLive.com (press release), FDA urges genetic test with Glaxo AIDS drug - Jul 24, 2008 WASHINGTON (Reuters) - AIDS patients should be tested before treatment with GlaxoSmithKline Plc's AIDS drug Ziagen for a genetic variant that raises the Reuters India, FDA urges genetic test before giving AIDS drug - Aug 6, 2008 ...on physicians to perform a genetic test on patients prior to prescribing the AIDS drug Abacavir, made by GlaxoSmithKline and sold under the name Ziagen. Westside Gazette Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to ... - Aug 7, 2008 If you stop EPZICOM because of an allergic reaction, NEVER take EPZICOM or any other abacavir-containing medicine (ZIAGEN, TRIZIVIR) again. MarketWatch Updated box warning for abacavir treatments - Jul 25, 2008 The boxed warning for GlaxoSmithKline's Ziagen (abacavir sulfate) and other abacavir-containing drugs has been updated to warn about the increased risk of Prescribing Reference, Gene Linked to Hypersensitivity Reaction to HIV/AIDS Drug - Jul 24, 2008 ...drug abacavir (Ziagen) should undergo pre-treatment genetic screening for the presence of an allele that may trigger a fatal hypersensitivity reaction. MedPage Today, FDA Recommends Genetic Screening Prior to Treatment With Abacavir - Jul 24, 2008 ...hypersensitivity reactions (HSRs) caused by abacavir (Ziagen) therapy in patients with a particular human leukocyte antigen (HLA) allele, HLA-B*5701. DG News WellPoint's earnings drop, but investors pleased; FDA recommends ... - Jul 24, 2008 Article > The FDA is recommending genetic testing before doctors prescribe an AIDS medication called Abacavir--sold as Ziagen--as part of the personalized FierceHealthcare, FDA: Test before giving GSK med - Jul 24, 2008 ...before prescribing abacavir, a GlaxoSmithKline anti-AIDS med sold under the brand name Ziagen and as part of the combo treatments Trizivir and Epzicom. FiercePharma, Need for vigilance: two cases of abacavir allergy despite pre ... - Jul 16, 2008 Healthcare workers and patients need to be vigilant about the possibility of an allergic reaction after starting abacavir (Ziagen), even if the HLA-B*5701 Aidsmap, SMART study and 54-trial pooled analysis produce conflicting data ... - Aug 7, 2008 Data from the SMART trial provide further evidence that abacavir (Ziagen) may be associated with a higher rate of cardiovascular events, Aidsmap, HBOS, Mitchells & Butlers, Rentokil: UK, Irish Equity Preview - Jul 24, 2008 GlaxoSmithKline Plc (GSK LN): Doctors prescribing Ziagen, a GlaxoSmithKline Plc drug for AIDS, were warned to test patients for a gene that raises the risk Bloomberg IAC: HIV Care Guidelines Expand Treatment Eligibility - Aug 3, 2008 The suggested nRTI combinations are tenofovir/emtricitabine (Viread/Emtriva) and abacavir/lamivudine (Ziagen/3TC). If abacavir is being considered, MedPage Today, Earnings Preview: Gilead Sciences - Jul 16, 2008 The journal concluded that Gilead competitor GlaxoSmithKline (nyse: GSK - news - people ) PLC's Ziagen increased patient's risk of heart attack by 90 Forbes, LabCorp May Benefit in HLA-Dx Space from FDA’s Call for Gene Data ... - Jul 30, 2008 The branded version drug, manufactured by GSK, is called Ziagen. GSK researchers used LabCorp’s PCR-based HLA-B*5701 test to genetically screen patients in Pharmacogenomics Reporter (subscription), Genetic Screening Recommended Before Abacavir HIV Therapy - Jul 25, 2008 ...reactions (HSRs) to abacavir sulfate (Ziagen, GlaxoSmithKline), the US Food and Drug Administration (FDA) advised healthcare professionals yesterday. Medscape (subscription) FDA: Doctors should use genetic test before prescribing abacavir - Jul 24, 2008 The recommendation will be included in a "black box" warning on Ziagen's new label, which will also mention the increased risk of heart attack based on SmartBrief, FDA: Doctors should use genetic test before prescribing abacavir - Jul 24, 2008 The recommendation will be included in a "black box" warning on Ziagen's new label, which will also mention the increased risk of heart attack based on SmartBrief, FDA: Doctors should use genetic test before prescribing abacavir - Jul 24, 2008 The recommendation will be included in a "black box" warning on Ziagen's new label, which will also mention the increased risk of heart attack based on SmartBrief, EEUU aconseja test genético antes de usar fármaco contra el sida ... - Jul 24, 2008 En los pacientes que dan positivo a una prueba sobre una variación genética especÃfica, el tratamiento con Ziagen "no se recomienda y deberÃa considerarse El Universal (Venezuela), EEUU aconseja test genético antes de usar fármaco sida de Glaxo - Jul 24, 2008 En los pacientes que dan positivo a una prueba sobre unavariación genética especÃfica, el tratamiento con Ziagen "no serecomienda y deberÃa considerarse EcoDiario.es, GSK 'AIDS' ì¹˜ë£Œì œ '지아ê²?' ìœ ì „ìž? 검사 필수 - Jul 24, 2008 ...글ë?½ì†ŒìŠ¤ë¯¸ìŠ¤í?´ë?¼ì?¸(GSK)사ì?˜ 지아ê²?(Ziagen) 치료를 받는 AIDS 환ìž?들ì?€ 약물 ë³µìš©ì „ ë¨¼ì € ìœ ì „ìž? 검사를 받아야 하는 것으로 나타났다. 25ì?¼ 미 FDA는 "íŠ¹ì • ìœ ì „ìž? Medical Today, Ã…rsag til problem med aidsmedicin fundet - Aug 8, 2008 Universitet mener at have fundet Ã¥rsagen til, at aidsmedicinen abacavir, som sælges under navnet Ziagen, giver øget risiko for hjerteproblemer. Fyens Stiftstidende, European markets may extend losses; global cues weak - Jul 24, 2008 In the UK market, GlaxoSmith Kline may see downside, as doctors prescribing Ziagen, the company's drug for AIDS, were warned to test patients for a gene Trading Markets (press release), Ã…rsag til problem med aidsmedicin fundet - Aug 8, 2008 Universitet mener at have fundet Ã¥rsagen til, at aidsmedicinen abacavir, som sælges under navnet Ziagen, giver øget risiko for hjerteproblemer. Randers Amtsavis, Espoirs en résistance majeure - Jul 31, 2008 Zérit® (stavudine ou D4T), Ziagen® (abacavir). Analogues nucléotidiques inhibiteurs de la transcriptase inverse : Viread® (tenofovir). Act Up-Paris, Drug for treating HIV may raise heart attack risk, manufacturer warns - Jun 23, 2008 GlaxoSmithKline, in conjunction with Health Canada, is advising patients taking abacavir-containing products - sold under the brand names Ziagen, The Canadian Press, U's Medical Devices Center: Incubator for invention - Jun 24, 2008 The U's patents on Ziagen, an anti-AIDS drug that generates 95 percent of the school's annual licensing income, will expire overseas next year and in the Minneapolis Star Tribune, Potential Risk of Cardiac Events in Patients Treated With Abacavir ... - Jun 25, 2008 ...in HIV-infected patients treated with abacavir-containing medicinal products (Ziagen, Kivexa, and Trizivir) has been released by Health Canada. DG News GSK warns of potential heart risk for HIV drug - Jun 25, 2008 26 issue of The Lancet, may show an increased risk of myocardial infarction with abacavir-containing products, such as Ziagen, Kivexa and Trizivir. Therapeutics Daily (subscription) (press release), Heart Risks Emerging in People With HIV - Jun 19, 2008 The US Food and Drug Administration said in March that it was studying the possibility of label changes for two HIV drugs, Ziagen and Videx, because studies Forbes, Around 10% of HIV-positive patients without hepatitis B virus or ... - Jun 20, 2008 ...and antiretroviral therapy that included ddI (didanosine, Videx) or abacavir (Ziagen, also in the combination pills Trizivir and Kivexa). Aidsmap, Brand Names/Synonyms: Ziagen is also known by the following brand names and/or synonyms: 1592U89; ABC; Abacavir; Abacavir [Inn]; Ziagen Drug Category: Ziagen is categorized under the following by the FDA: Anti-HIV Agents; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; ATC:J05AF06 Dosage Forms: SOLUTION; TABLET Absorption: Rapid and extensive after oral administration (83% bioavailability) Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: [4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-1-cyclopent-2-enyl]methanol |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
